Companies /Healthcare
Incyte Corp
NASDAQ: INCY Biotechnology
$116.87
▲ $0.27 (+0.23%) today
Markets closed · 7:00pm ET

Incyte (INCY) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
83%
EPS beat rate
+21.36%
Avg. EPS surprise
Consecutive EPS beats
INCY vs Market · 30-day return after each reportINCYS&P 500
−7%0%+7%+14%+7.7%+6.3%Q1 25+8.2%+2.2%Q2 25+14.0%−0.5%Q3 25−7.5%−4.3%Q4 25−1.0%+6.3%Q1 26−1.7%+4.1%Q2 26
−7%0%+7%+14%Q1 25Q3 25Q1 26
INCY EPS Trend · estimate vs actualEstimateActual
$0.00$0.90$1.80$2.70$1.05$1.16Q1 25$1.47$1.57Q2 25$1.64$2.26Q3 25$1.92$1.80Q4 25$1.34$1.81Q1 26$2.15$3.09Q2 26
$0.00$0.90$1.80$2.70Q1 25Q3 25Q1 26
INCY Revenue Trend · estimate vs actualEstimateActual
$0$500.0M$1.0B$1.5B$996.6M$1.1BQ1 25$1.1B$1.2BQ2 25$1.3B$1.4BQ3 25$1.4B$1.5BQ4 25$1.2B$1.3BQ1 26$1.5B$1.7BQ2 26
$0$500.0M$1.0B$1.5BQ1 25Q3 25Q1 26

How Often Does Incyte Beat Earnings Estimates?

Incyte beat EPS estimates in 5 of its last 6 reported quarters, and has beaten 2 quarters in a row.

INCY quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 $3.09 est. $2.15 +43.95% $1.7B est. $1.5B +12.50%
Q1 2026 $1.81 est. $1.34 +35.13% $1.3B est. $1.2B +5.07%
Q4 2025 $1.80 est. $1.92 −6.08% $1.5B est. $1.4B +11.33%
Q3 2025 $2.26 est. $1.64 +38.04% $1.4B est. $1.3B +8.96%
Q2 2025 $1.57 est. $1.47 +6.48% $1.2B est. $1.1B +5.81%
Q1 2025 $1.16 est. $1.05 +10.62% $1.1B est. $996.6M +5.65%

Figures from SEC filings and company reports. Not investment advice.